Table 1 Baseline patient characteristics and treatment
From: Proctitis following stereotactic body radiation therapy for prostate cancer
% Patients (N = 269) | ||
|---|---|---|
Age (y/o) | Median 69 (44-90) | Â |
| Â | <60 | 8.20% |
| Â | 60-69 | 42.40% |
| Â | 70-79 | 41.30% |
|  | ≥80 | 8.20% |
Race | Â | Â |
| Â | White | 55.80% |
| Â | Black | 37.20% |
| Â | Other | 7.10% |
Prostate volume (cc) | Median 39.04 | Â |
(11.56-138.69) | Â | |
Charlson comorbidity index (CCI) | Â | Â |
| Â | 0 | 66.9% |
| Â | 1 | 22.7% |
| Â | 2 | 6.7% |
|  | ≥3 | 3.7% |
Body mass index | Â | Â |
| Â | BMI <25 | 21.9% |
|  | 25 ≤ BMI < 30 | 47.2% |
|  | 30 ≤ BMI < 35 | 21.9% |
|  | BMI ≥35 | 8.9% |
Use of anticoagulants | Yes | 35.3% |
| Â | No | 64.7% |
Risk group | Â | Â |
| Â | Low | 36.80% |
| Â | Intermediate | 53.20% |
| Â | High | 10.00% |
Hormonal therapy | Â | Â |
| Â | Yes | 16.40% |
| Â | No | 83.60% |
Dose | Â | Â |
| Â | 36.25Â Gy | 83.30% |
| Â | 35Â Gy | 16.40% |
| Â | Other | 0.40% |